Mark Miller, MD
Allergy · Hoffman Estates, ILNPI 1508894585
Payments from drug & device makers
Across 800 payments — averaging $21.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$4K
- AstraZeneca$4K
- Regeneron Healthcare Solutions, Inc.$2K
- CSL Behring$2K
- Sanofi$904
- Genentech USA, Inc.$648
- plus $5K from 24 others
What the payments were for
- Food & beverage$17,09899%
- Education$2051%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 206 | $3,818 |
| AstraZeneca | 131 | $3,546 |
| Regeneron Healthcare Solutions, Inc. | 57 | $1,813 |
| CSL Behring | 84 | $1,641 |
| Sanofi | 41 | $904 |
| Genentech USA, Inc. | 24 | $648 |
| Optinose US, Inc. | 51 | $610 |
| Biocryst US Sales Co., LLC | 31 | $585 |
| Covis Pharma GmbH | 21 | $439 |
| Boehringer Ingelheim | 21 | $426 |
| Takeda Pharmaceuticals U.S.A., Inc. | 16 | $413 |
| Kaleo, Inc. | 19 | $395 |
| Amgen | 13 | $302 |
| ARS Pharmaceuticals Operations, Inc. | 14 | $292 |
| Pfizer | 18 | $290 |
| Novartis | 12 | $275 |
| Pharming Healthcare, Inc. | 9 | $180 |
| Teva Pharmaceuticals USA, Inc. | 7 | $153 |
| Shire North American Group Inc | 4 | $89 |
| Blueprint Medicines Corporation | 3 | $76 |
| Stryker | 1 | $61 |
| Alk-abello, Inc | 3 | $59 |
| Cycle Pharmaceuticals Inc | 2 | $54 |
| Ionis Pharmaceuticals, Inc. | 2 | $50 |
| Hikma Pharmaceuticals USA | 2 | $45 |
| Merck | 3 | $45 |
| Aimmune Therapeutics, Inc. | 2 | $38 |
| USWM, LLC | 1 | $25 |
| Biocryst Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$17,302 in reported general payments places this provider in the 85th percentile of 47 allergy providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 23 | $86,966 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $81,093 |
| Breo ElliptaFluticasone/Vilanterol | 119 | $67,857 |
| XolairOmalizumab | 20 | $55,829 |
| Arnuity ElliptaFluticasone Furoate | 62 | $23,230 |
| DuleraMometasone/Formoterol | 28 | $17,012 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 47 | $13,722 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $13,087 |
| Advair HfaFluticasone Propion/Salmeterol | 29 | $11,721 |
| Incruse ElliptaUmeclidinium Bromide | 17 | $7,282 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 59 | $7,159 |
| Wixela InhubFluticasone Propion/Salmeterol | 30 | $6,214 |
| Azelastine Hcl | 162 | $4,618 |
| Ipratropium Bromide | 138 | $3,798 |
| Azelastine-FluticasoneAzelastine/Fluticasone | 21 | $3,299 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta, Incruse Ellipta | $3,818 | $179,462278 claims |
| MerckDulera | $45 | $17,01228 claims |
| AstraZenecaSymbicort | $3,546 | $13,08749 claims |
| Hikma Pharmaceuticals USAEpinephrine | $45 | $2,92015 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 47 allergy providers in Illinois.
Other allergy in Hoffman Estates
- Ewa SchaferGlenview$165K
- Brian RotskoffChicago$82K
- Bruce BochnerChicago$69K
- Edward LisbergChicago$45K
- Renu GovindaiahSpringfield$32K
- Mohammad GhaniWestchester$16K
- Sai NimmagaddaOrland Park$14K
- Archana NarayanJoliet$11K
- Alan ResnickOrland Park$9K
- Alex ThomasChicago$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.